MARCIO CORREA MANCINI

(Fonte: Lattes)
Índice h a partir de 2011
16
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/18 - Laboratório de Carboidratos e Radioimunoensaios, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2017 ×

Resultados de Busca

Agora exibindo 1 - 7 de 7
  • article 11 Citação(ões) na Scopus
    Assessment of Weight Loss With the Intragastric Balloon in Patients With Different Degrees of Obesity
    (2017) NUNES, Gabriel C.; PAJECKI, Denis; MELO, Maria E. De; MANCINI, Marcio C.; CLEVA, Roberto De; SANTO, Marco A.
    Introduction: The intragastric balloon (IGB) is an endoscopic device for the treatment of obesity. Best results are observed in patients who follow a dietary program but few studies have assessed the results of this treatment in patients with different degrees of obesity. Aim: The aim of this study is to compare the efficacy of IGB in patients with different degrees of obesity. Method: A total of 2002 patients with IGB were retrospectively evaluated and were divided into groups according to initial body mass index (BMI) range, as follows: group 1, 27 to 29.9 kg/m(2); group 2, 30 to 34.9 kg/m(2); group 3, 35 to 39.9 kg/m(2); group 4, 40 to 44.9 kg/m(2); group 5, >= 45 kg/m(2). Weight was assessed in 3 different times: before (T0), 1 month (T1), 6 months (T2), and 6 months after removal of the IGB (T3). Results: A total of 946 patients lost follow-up. Overall, 40 (3.78%) removed the device before programmed by intolerance, and 1016 patients completed the 6-month treatment. The mean weight loss was 18.9%, excess weight loss 60.1% and an BMI reduction of 6.76 points. 6 months after removal of the balloon 842 patients had continued follow-up (82.8%). At this time, weight loss was 19.84%, excess weight loss was 59.49%, and BMI reduction of 7.06 points. In all groups there was statistical difference between the times T0 and T1 and between T1 and T2 (P < 0.001). There was no statistical difference between T2 and T3, in any group. Conclusion: IGB provided sustained weight loss in patients who remained in dietary follow-up for 1 year.
  • article 8 Citação(ões) na Scopus
    Effects of two diet techniques and delivery mode on weight loss, metabolic profile and food intake of obese adolescents: a fixed diet plan and a calorie-counting diet
    (2017) MENDES, M. D. S. D.; MELO, M. E. de; FERNANDES, A. E.; FUJIWARA, C. T. H.; PIOLTINE, M. B.; TEIXEIRA, A.; COELHO, K.; GALASSO, M.; CERCATO, C.; MANCINI, M. C.
    The aim of this study is to compare the weight loss of obese adolescents on two different low-calorie diets: fixed diet plan and calorie-counting diet. This is a randomized clinical study with 66 obese adolescents (body mass index Z score (ZBMI) > + 3, 13.7 +/- 0.7 years, 60.6% male) with anthropometric, food intake, physical activity, laboratory, body composition and stage of pubertal development data evaluated. There was a reduction in the ZBMI in both groups (P < 0.0001), without significant difference between them (P = 0.87). There was a significant reduction in insulin, and homeostasis model assessment insulin resistance (HOMA-IR), with no difference between groups. A reduction in total energy intake of the groups was found, with an increase in the proportion of protein and reduction in carbohydrates. In this cohort of severely obese adolescents, fixed diet plan and calorie-counting diet led to a similar reduction of ZBMI, metabolic markers and total energy intake.
  • article 2 Citação(ões) na Scopus
  • article 34 Citação(ões) na Scopus
    The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg
    (2017) MANCINI, Marcio C.; MELO, Maria Edna de
    The prevalence of obesity increases worldwide. Treating obesity and its associated health problems has a significant economic impact on health care systems. The unsatisfactory long-term outcomes observed in the obesity treatment are due to its complex pathophysiology and the inherent difficulties associated with maintenance of lifestyle modifications. Determined by genetic and environmental factors, obesity has been officially recognized as a chronic disease, an action that allowed the recognition of anti-obesity drugs as legitimate therapeutic options to address the growing obesity endemic. Like other chronic diseases, obesity requires long-term treatment. Pharmacological interventions, when used as an adjunct to lifestyle changes, are useful to facilitate clinically meaningful weight loss, which may impact on obesity-associated comorbid conditions. In the past, medications for weight reduction were limited. However, the landscape has changed and new drugs provide additional options for weight management. Among the new drugs, liraglutide is the most studied, especially regarding its effects on the limbic system. As an adjunct to a reduced-calorie diet and increased physical activity, treatment with liraglutide 3.0 mg provides a statistically significant and clinically meaningful weight loss. Liraglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist that shares 97% homology to native GLP-1. Receptor agonists of GLP-1, including liraglutide, have emerged as effective therapies for type 2 diabetes and obesity. This review will address the major findings concerning the central regulation of appetite and the main studies that evaluated new drugs for obesity treatment, with a greater focus on liraglutide 3.0 mg.
  • article 33 Citação(ões) na Scopus
    Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release
    (2017) HALPERN, Bruno; MANCINI, Marcio C.
    Introduction: Few studies on combination therapies for the treatment of obesity had been conducted until recently, when two fixed-dose combinations, bupropion-naltrexone ER fixed-dose combination and phentermine-topiramate ER titrated-dose combinations were evaluated in clinical studies that ultimately led to FDA approval. Areas covered: In this review, we discuss safety concerns about both combinations, the rationale and history of combination therapies for obesity (including phentermine plus fenfluramine), and possible future new combinations. Expert opinion: Combination therapies are a promising new area in obesity treatment, similar to what occurs with diabetes and hypertension. Safety assessment is highly important due to the high number of potential users on a chronic basis.
  • bookPart
    Tratamento clínico da obesidade
    (2017) MANCINI, Marcio Corrêa
  • bookPart